Related Experiment Video
Updated: Jun 12, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
[Chemotherapy with docetaxel in prostate cancer. A case report]
E Lechevallier1, S Culine, A Benchikh El Fegoun
1Service d'urologie, hôpital de la Conception, boulevard Baille Marseille cedex 5, France.
Abstract:
There is nothing to support Docetaxel as a first line treatment in metastatic prostate cancer. Hormonal treatment is still the gold standard. Chemotherapy should be initiated in symptomatic patients or if patients are at high risk of developing metastasis (PSADT < 3 months). Quality of life is the main endpoint of chemotherapy in metastatic prostate cancer, that should be monitored clinically. The dose of Docetaxel should be adapted according to the geriatric evaluation in elderly patients. Estramustine is still under evaluation. There is no gold standard for second line chemotherapy in castrate resistant prostate cancer. In this situation patients should be included in protocols.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Treatment Resistent Cancers
Drugs that Stabilize Microtubules

